MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Most important demo aims ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people, though one of the https://andresetbkq.daneblogger.com/30176000/the-2-minute-rule-for-qst4